Price
$71.35Social Signal Score
Analyst Ratings
10 analysts52-week range
- Last close
- $71.35
- Off 52w high
- -21.6%
- 200-day average
- $49.70
- vs 200-day
- +43.6%
Revenue
$225.30M+13644.72%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Roger A. Jeffs
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Employees
- 216
- Beta
- 0.54
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 3.31
Financials
Revenue
$225.30M+13644.7%Net Income
$-236.33MEBITDA
$-262.97MFree Cash Flow
$129.78MEPS (diluted)
$-2.64Shares Outstanding (diluted)
89.52M+942.6%Operating Expenses
$84.29MCash & Debt
$396.09MReturn of Capital
$0.00Revenue by Segment (annual)
$158.32MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $158.32M | $-68.92M | $-0.80 |
| 2024 | $14.00M | $-130.39M | $-1.66 |
| 2023 | $17.49M | $-78.50M | $-1.21 |
| 2022 | $15.94M | $-41.02M | $-0.67 |
| 2021 | $12.85M | $-34.58M | $-0.70 |
| 2020 | $739.6K | $-59.76M | $-1.76 |
| 2019 | $8.07M | $-47.58M | $-2.51 |
| 2018 | $2.71M | $-53.14M | $-7.42 |
| 2017 | $7.26M | $-29.15M | $-3.40 |
| 2016 | $13.22M | $-15.93M | $-1.86 |
Valuation
LQDAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
63-3.85%Social Signal Score
Mentions (58)
- News (RSS)seekingalpha·8d ago·Neutral
Liquidia: Yutrepia's PAH Franchise Has Room To Grow
View source ↗ - Newsseekingalpha.com·8d ago·Neutral
Liquidia: Yutrepia's PAH Franchise Has Room To Grow Liquidia kept the right to market YUTREPIA for PAH after the settlement with United Therapeutics. This settlement limits YUTREPIA's potential in PH-ILD, but since it can still be sold to patients using it and to patients with PAH, Liquidia Corporation can continue generating revenue. YUTREPIA is already generating cash. Paid PAH starts will show how much of the lost PH-ILD growth LQDA can replace.
View source ↗ - News (Marketaux)seekingalpha.com·11d ago·Positive
Liquidia stock upgraded at Raymond James (LQDA:NASDAQ) Shares of Liquidia Corporat[+250 characters]
View source ↗ - Newszacks.com·11d ago·Neutral
LQDA Q3 Earnings Call Highlights Growth and Post-Settlement Outlook Liquidia reports surging YUTREPIA sales, record October shipments and expanding PAH adoption amid post-settlement market changes and referral disruptions.
View source ↗ - News (RSS)investing·12d ago·Neutral
Liquidia Q3 2026 slides: YUTREPIA sales surge 31% amid settlement
View source ↗ - Newsmarketbeat.com·12d ago·Neutral
Liquidia Q3 Earnings Call Highlights Liquidia NASDAQ: LQDA reported a 31% sequential increase in third-quarter YUTREPIA sales as the company sought to reassure investors that its pulmonary arterial hypertension business can continue growing following a patent settlement with United Therapeutics.
View source ↗ - Newsseekingalpha.com·12d ago·Positive
Liquidia Corporation (LQDA) Q3 2026 Earnings Call Transcript Liquidia Corporation (LQDA) Q3 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·12d ago·Neutral
Liquidia Corporation (LQDA) Q3 Earnings and Revenues Beat Estimates Liquidia Corporation (LQDA) came out with quarterly earnings of $0.8 per share, beating the Zacks Consensus Estimate of $0.77 per share. This compares to a loss of $0.04 per share a year ago.
View source ↗ - Newsglobenewswire.com·12d ago·Neutral
Liquidia Corporation Reports Third Quarter 2026 Financial Results MORRISVILLE, N.C., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today reported financial results for the third quarter ended September 30, 2026. The company will also host a webcast at 8:30 a.m. ET on November 10, 2026, to discuss its financial results and pro…
View source ↗ - Newsglobenewswire.com·19d ago·Neutral
…ia Corporation to Report Third Quarter 2026 Financial Results on November 10, 2026 MORRISVILLE, N.C., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, announced today that it will report its third quarter 2026 financial results on Tuesday, November 10, 2026. The company will host a live webcast at 8:30 a.m. Eastern Time to discu…
View source ↗ - Newszacks.com·25d ago·Neutral
Liquidia Gears Up to Report Q3 Earnings: What Can Investors Expect? LQDA's Q3 results will spotlight the impact of its legal settlement with UTHR, cash flow pressures, profitability prospects and pipeline progress.
View source ↗ - Newszacks.com·39d ago·Negative
LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label Liquidia settles six legal disputes with United Therapeutics, securing Yutrepia access for PAH patients but facing $380.7 million in payments and a narrower drug label.
View source ↗ - Newsproactiveinvestors.com·39d ago·Neutral
Liquidia shares surge 25% as settlement ends United Therapeutics litigation Liquidia Corporation (NASDAQ:LQDA), the biopharmaceutical company, surged 25% to $33.47 after settling all six pending lawsuits with United Therapeutics Corporation (NASDAQ:UTHR), ending years of patent and antitrust disputes. The agreement removes a major source of legal uncertainty surrounding YUTREPIA, Liquidia's inhaled treprostinil treatment for pulmonary arterial hypertension, a condition involving high blood press…
View source ↗ - News247wallst.com·39d ago·Neutral
United Therapeutics and Liquidia Just Ended Their Patent War. Liquidia Stock Popped 42% A patent court ruling wiped out nearly half of Liquidia's stock value in a single day, and the settlement that followed cost the company almost every dollar it had in the bank.
View source ↗ - Newsglobenewswire.com·40d ago·Negative
… with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH MORRISVILLE, N.C., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced that it has entered into a global settlement agreement with United Therapeutics Corporation (Nasdaq: UTHR) that resolves all pending litigation between the compani…
View source ↗ - Newsbusinesswire.com·46d ago·Negative
LQDA Investors with $100,000 in Losses Have Opportunity to Join Liquidia Corporation Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $LQDA--LQDA Investors with $100,000 in Losses Have Opportunity to Join Liquidia Corporation Fraud Investigation with SBS Law.
View source ↗ - Newszacks.com·52d ago·Negative
Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback LQDA faces a major setback as a patent ruling threatens Yutrepia's PH-ILD indication and creates uncertainty around its commercial outlook.
View source ↗ - News247wallst.com·52d ago·Negative
United Therapeutics Won Its Patent War and Liquidia Collapsed A single court ruling sent one pulmonary hypertension drugmaker soaring and left its rival fighting for survival, but the legal battle over Yutrepia's future is far from settled.
View source ↗ - News (Marketaux)gurufocus.com·53d ago·Positive
Liquidia (LQDA) Shares Drop 52% After Delaware Court Patent Ruling On September 30, 2026, Liquidia[+253 characters]
View source ↗ - Newsbusinesswire.com·53d ago·Positive
United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the United States District Court for the District of Delaware issued an opinion that finds Liquidia Technologies, Inc. (Liquidia) infringes two claims of United Therapeutics' patent covering the use of inhaled treprostinil to treat pulmonary hypertension
View source ↗ - News (Marketaux)gurufocus.com·53d ago·Neutral
Delaware Court Ruling Boosts MannKind (MNKD) Outlook Amid Liquidia Patent Dispute Delaware Court Ruling Boosts MannKind (MNKD) Outlook Amid Liquidia Patent Dispute
View source ↗ - News (RSS)investing·53d ago·Neutral
Liquidia shares crater after court rules for United Therapeutics
View source ↗ - News (RSS)investing·53d ago·Neutral
Liquidia loses patent infringement case on two claims
View source ↗ - Newsreuters.com·53d ago·Negative
Liquidia slumps after US court rules for United Therapeutics in patent fight Liquidia shares plunged nearly 50% on Wednesday after a federal judge ruled that its lung drug infringes key patent held by rival United Therapeutics , dealing a major blow to the treatment's commercial outlook.
View source ↗ - Newsseekingalpha.com·53d ago·Positive
Liquidia: Bullish On Their Growth Potential Despite YUTREPIA's Legal Tail Risk YUTREPIA's adoption is translating into profits and cash, giving Liquidia an operating foundation for further growth. LQDA is already generating substantial cash flows, even though YUTREPIA's growth phase remains in its early stages. The main risk I believe is worth monitoring is LQDA's ongoing legal battle with UTHR over potential patent infringement.
View source ↗ - Newszacks.com·53d ago·Positive
LQDA versus ALKS: Which Biotech Stock Is the Better Buy Now? LQDA's Yutrepia drives rapid growth, while ALKS benefits from a diversified portfolio, Lumryz and a broader pipeline.
View source ↗ - Newsglobenewswire.com·53d ago·Positive
…fying the proposed remedy, for the District Court's consideration within one week MORRISVILLE, N.C., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today issued an update regarding the litigation filed by United Therapeutics Corporation (UTHR) in the U.S. District Court for the District of Delaware (the Court) under the Hatch…
View source ↗ - News (Marketaux)gurufocus.com·54d ago·Positive
Liquidia Corporation (LQDA) Surges Nearly 8% Amid Sector Gains on September 28, 2026 On September 28, 2026, Liquidia[+311 characters]
View source ↗ - Newszacks.com·60d ago·Negative
Can LQDA's Yutrepia Outpace Intensifying PAH Competition? Liquidia's Yutrepia posts rapid sales growth, but intensifying competition from established therapies and emerging drugs could test its momentum.
View source ↗ - Newszacks.com·72d ago·Negative
LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now? Liquidia's Yutrepia is gaining traction, but patent litigation, competition, rising costs and heavy product dependence cloud LQDA's outlook.
View source ↗ - Newszacks.com·73d ago·Negative
Can a Potential Label Expansion of Yutrepia Boost LQDA's Portfolio? Liquidia's Yutrepia wins FDA Fast Track status for SSc-related Raynaud's, opening a potential new growth avenue for the lead drug.
View source ↗ - News (RSS)yahoo·80d ago·Neutral
Liquidia Corporation’s (LQDA) Yutrepia Launch Continues to Outpace the Expectations
View source ↗ - News (Marketaux)gurufocus.com·80d ago·Neutral
LQDA Looks 75.0% Undervalued on GF Value™ On September 03, 2026, Liquidia[+313 characters]
View source ↗ - Newsglobenewswire.com·81d ago·Neutral
Liquidia to Present Posters at the European Respiratory Society (ERS) 2026 Congress MORRISVILLE, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced that it will present two posters at the European Respiratory Society (ERS) 2026 Congress taking place September 5-9, 2026, in Barcelona, Spain.
View source ↗ - Newsglobenewswire.com·82d ago·Neutral
Liquidia Corporation to Participate in Wells Fargo Annual Healthcare Conference MORRISVILLE, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced that Michael Kaseta, Chief Operating Officer and Chief Financial Officer, and Jason Adair, Chief Business Officer, will provide an update on the company's business in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference in Boston on Tuesday, September 8, 2026 at 8:45 a.m.
View source ↗ - Newszacks.com·83d ago·Neutral
Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition? Liquidia's Yutrepia is driving rapid growth, but fierce PAH competition and new pipeline therapies could challenge its momentum.
View source ↗ - Newszacks.com·83d ago·Negative
Is the Options Market Predicting a Spike in Liquidia Stock? Investors need to pay close attention to LQDA stock based on the movements in the options market lately.
View source ↗ - Newsseekingalpha.com·86d ago·Negative
Liquidia: A Linear Launch Priced For Exponential Growth Liquidia Corporation is rated Sell due to YUTREPIA's decelerating growth and an overextended $6B+ valuation. YUTREPIA's percentage growth is compressing, prescriber acquisition has halved, and launch-era tailwinds are fading. Future growth will require difficult community penetration and overcoming structural headwinds from patient mortality and discontinuation.
View source ↗ - Newszacks.com·87d ago·Positive
Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now? Liquidia's Yutrepia is driving strong growth, but Insmed's Brinsupri and broader pipeline could make it the better long-term pick.
View source ↗ - Newszacks.com·90d ago·Neutral
Will LQDA's Differentiated PAH Approach Drive Growth? LQDA's Yutrepia is driving rapid growth, but intensifying PAH competition could test its ability to sustain momentum.
View source ↗ - Newsgurufocus.com·94d ago·Neutral
Liquidia Corp (LQDA) Shares Fall 5.8% -- What GF Score of 70 Tells Investors On August 20, 2026, Liquidia Corp (LQDA) shares fell 5.8% to $71.05, continuing a downward trend from its 52-week high of $93.61, while still reflecting a subst
View source ↗ - Newszacks.com·95d ago·Positive
Can Yutrepia's Strong Growth Drive Liquidia's PAH Expansion? Liquidia's Yutrepia is gaining traction, with $300.3M in first-half sales and nearly 30% of inhaled-market revenues in Q2.
View source ↗ - News (RSS)fool·95d ago·Positive
Liquidia (LQDA) Q2 2026 Earnings Call Transcript YUTREPIA sales hit $170.4 million with 5,000+ patients started on therapy.
View source ↗ - Newszacks.com·97d ago·Neutral
LQDA Stock Down Post Q2 Earnings Release: What Should Investors Do Now? Liquidia's Yutrepia is fueling rapid growth, but patent litigation, competition and heavy product dependence weigh on its outlook.
View source ↗ - News (RSS)yahoo·97d ago·Neutral
Greenhaven Road Capital: Short Term Gain Realized from Liquidia (LQDA), Investment to Be Revisited
View source ↗ - Newsfool.com·100d ago·Negative
Why Liquidia Stock Was Diving This Week The shares had risen by 155% year-to-date prior to earnings. Regardless, its one commercialized drug is doing well by any measure.
View source ↗ - Newszacks.com·101d ago·Positive
LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth Yutrepia sales fuel Liquidia's Q2 growth as revenues surge and profitability rises, while the company targets more than $1 billion in 2027 revenues.
View source ↗ - Newszacks.com·101d ago·Positive
LQDA Q2 Earnings Call Highlights YUTREPIA and $1B 2027 Revenue Path Liquidia targets more than $1 billion in 2027 net revenues as YUTREPIA gains share and funds a broader inhaled-treprostinil pipeline.
View source ↗ - News (RSS)seekingalpha·101d ago·Neutral
Liquidia: YUTREPIA's Launch Opens Upside If Growth Remains And Margins Follow
View source ↗ - Newsseekingalpha.com·101d ago·Neutral
Liquidia: YUTREPIA's Launch Opens Upside If Growth Remains And Margins Follow YUTREPIA's commercial launch continues to scale, with Q2 product sales of $170.4 million, up 31% sequentially. Q2 largely resolved the margin concern: product gross margin remained about 93.7% despite fully costed inventory, while operating margin reached roughly 49.8%. The key debate has shifted from profitability to growth. Liquidia now needs about $210 million of quarterly revenue in Q3 and Q4 to reach the current $…
View source ↗ - News (RSS)yahoo·102d ago·Neutral
Liquidia Corporation Q2 2026 Earnings Call Summary
View source ↗ - News (RSS)investing·102d ago·Neutral
Liquidia Q2 2026 slides: YUTREPIA sales surge 31%, 10 studies underway
View source ↗ - Newsseekingalpha.com·102d ago·Positive
Liquidia Corporation (LQDA) Q2 2026 Earnings Call Transcript Liquidia Corporation (LQDA) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·102d ago·Neutral
Liquidia Q2 Earnings Call Highlights Liquidia NASDAQ: LQDA reported second-quarter 2026 results marked by continued growth for its inhaled treprostinil product YUTREPIA, increased profitability and expanding investment in its clinical pipeline.
View source ↗ - Newszacks.com·102d ago·Neutral
Liquidia Corporation (LQDA) Q2 Earnings and Revenues Beat Estimates Liquidia Corporation (LQDA) came out with quarterly earnings of $0.74 per share, beating the Zacks Consensus Estimate of $0.7 per share. This compares to a loss of $0.49 per share a year ago.
View source ↗ - Newsglobenewswire.com·102d ago·Neutral
Liquidia Corporation Reports Second Quarter 2026 Financial Results YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $170.4 million in the second quarter of 2026, up 31% from the first quarter of 2026 Approximately 5,900 unique patient prescriptions and more than 5,000 patients treated between launch in June 2025 and July 31, 2026 Recorded fourth consecutive quarter of increasing profitability, with net income of $74.7 million, adjusted EBITDA of $96.3 million and an
View source ↗ - News (RSS)seekingalpha·103d ago·Neutral
Liquidia Q2 2026 Earnings Preview
View source ↗ - Newszacks.com·104d ago·Neutral
3 Low-Beta Stocks to Minimize Portfolio Risk: LQDA, PBF & FET Liquidia, PBF Energy and Forum Energy Technologies pair low beta with positive momentum and growth drivers amid market volatility.
View source ↗
Earnings
Thu, Mar 4(in 3 months)
Consensus estimate $0.97 per share
Typical surprise +29.3% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 10$-2.64 vs $0.96miss
- Wed, Aug 12$0.74 vs $0.70beat
- Mon, May 11$0.52 vs $0.34beat
- Thu, Mar 5$0.15 vs $0.08beat
- Mon, Nov 3$-0.04 vs $-0.45beat
- Tue, Aug 12$-0.49 vs $-0.43miss
Estimates and results for LQDA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by LQDA officers and directors.
- Bought
- —
- Sold
- $52.1m
0 trades
37 trades
- Boyle Danasold
- Adair Jasonsold
- Schundler Russellsold
- Saggar Rajeevsold
- Moomaw Scottsold
- Krepp Sarahsold
- Khindri Sanjeevsold
- Kaseta Michaelsold
63 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in LQDA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
